Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT01154881
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01151072
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01135927
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 143
- Registration Number
- NCT01135992
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Olympia, Washington, United States
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT01114542
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 493
- Registration Number
- NCT01079234
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT01076634
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 467
- Registration Number
- NCT01076647
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Satu Mare, Romania
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 456
- Registration Number
- NCT01074268
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 460
- Registration Number
- NCT01068665
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.